Ann Rheum Dis. 2022. Epub ahead of print [05/12/2022] doi: 10.1136/ard-2022-223356
Smolen, et al. provide a 2022 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs.
Since their initial development in 2010, updates to the EULAR recommendations have been produced every 3 years as insights have evolved, and new classification criteria, definitions of remission, treatment strategies, and drugs have emerged.
The task force agreed on 5 overarching principles and 11 recommendations concerning use of csDMARDs, GCs, bDMARDs and tsDMARDs.